Cyclerion - Logo - Blue.png
Tisento Launches with $81 Million From Top-Tier Investor Syndicate and Promising Cyclerion Assets
July 31, 2023 07:00 ET | Cyclerion Therapeutics, Inc.
        – Asset Purchase Agreement Closed; Cyclerion Received Equity Ownership in Tisento and Upfront Cash Payment – – Tisento Developing Zagociguat in MELAS*, a Rare Primary Mitochondrial Disease...
Cyclerion - Logo - Blue.png
Cyclerion Regains Compliance with Nasdaq Minimum Bid Price Requirement
June 01, 2023 16:00 ET | Cyclerion Therapeutics, Inc.
CAMBRIDGE, Mass., June 01, 2023 (GLOBE NEWSWIRE) -- Cyclerion Therapeutics, Inc. (“Cyclerion” or the “Company”) (Nasdaq: CYCN) today announced that it has received a formal notice from The Nasdaq...
Cyclerion - Logo - Blue.png
Cyclerion Announces Reverse Stock Split
May 15, 2023 13:00 ET | Cyclerion Therapeutics, Inc.
CAMBRIDGE, Mass., May 15, 2023 (GLOBE NEWSWIRE) -- Cyclerion Therapeutics, Inc. (the “Company”, “Cyclerion Therapeutics”, “Cyclerion”) (Nasdaq: CYCN) announced today that it will effect a reverse...
Cyclerion - Logo - Blue.png
Cyclerion Announces Corporate Updates and Q1 2023 Financial Results
May 11, 2023 18:00 ET | Cyclerion Therapeutics, Inc.
Definitive agreement reached with new company (“NewCo”) established by certain Cyclerion shareholders and new investors Cyclerion to receive $8M in cash and 10% equity in NewCo in exchange for its...
Cyclerion - Logo - Blue.png
Cyclerion Therapeutics Enters into Exclusive Negotiation Period and Binding Equity Investment Agreement
April 03, 2023 07:30 ET | Cyclerion Therapeutics, Inc.
CAMBRIDGE, Mass., April 03, 2023 (GLOBE NEWSWIRE) -- Cyclerion Therapeutics, Inc. (Nasdaq: CYCN) today announced that the Board of Directors of the Company, acting solely by all of its independent...
Cyclerion - Logo - Blue.png
Cyclerion Concludes Unsolicited Proposal Is Not in The Best Interest of The Company
November 22, 2022 07:00 ET | Cyclerion Therapeutics, Inc.
CAMBRIDGE, Mass., Nov. 22, 2022 (GLOBE NEWSWIRE) -- Cyclerion Therapeutics, Inc. (Nasdaq: CYCN) today announced that the Board of Directors of the Company acting solely by all of its independent and...
Cyclerion - Logo - Blue.png
Cyclerion Announces Mitochondrial Disease-Focused Corporate Strategy
October 06, 2022 08:00 ET | Cyclerion Therapeutics, Inc.
Recent positive MELAS clinical study data drive urgency to deliver potential first-ever therapy for patients with rare, genetic mitochondrial diseases Development programs prioritized and...
Cyclerion - Logo - Blue.png
Cyclerion Announces CY6463 Clinical Pipeline Progress and Second Quarter 2022 Financial Results
August 09, 2022 16:00 ET | Cyclerion Therapeutics, Inc.
Positive topline results for CY6463 announced in two clinical studies in patients with Mitochondrial Encephalomyopathy, Lactic Acidosis and Stroke-like episodes (MELAS) and Cognitive Impairment...
Cyclerion - Logo - Blue.png
Cyclerion Therapeutics Announces Positive Topline Clinical Data for CY6463 in Patients with Cognitive Impairment Associated with Schizophrenia (CIAS)
July 28, 2022 07:00 ET | Cyclerion Therapeutics, Inc.
Study data demonstrate positive effects of CY6463 on cognition and inflammation after two weeks of dosing in patients with stable schizophrenia on standard of care Oral, once-daily CY6463 was well...
Cyclerion - Logo - Blue.png
Steven E. Hyman, M.D., Appointed to Cyclerion Therapeutics’ Board of Directors
July 26, 2022 07:00 ET | Cyclerion Therapeutics, Inc.
CAMBRIDGE, Mass., July 26, 2022 (GLOBE NEWSWIRE) -- Cyclerion Therapeutics, Inc. (Nasdaq: CYCN), a clinical-stage biopharmaceutical company on a mission to develop treatments that restore cognitive...